PurThread Technologies has closed an equity round totaling just over $7 million. The investment was led by PurThread board chair Richard Bodman with a select group of investors. Funding will be put toward the growth, research and development of PurThread’s technologies designed to reduce bioburden in the hospital environment.

“The markets for PurThread’s innovative technology and products are compelling. We are pleased to support the company’s goal of continuously reducing the level of bioburden in hospital environments,” says Bodman. “Antimicrobial resistance is on the rise, leading hospitals to focus on additional ways to reduce the spread of infection. Just look at what has happened with the hand sanitizer market. We’re excited about the expansion of PurThread’s current product offerings and the promise of PurThread’s research into future applications.”

In PurThread’s process, each fiber is embedded with a proprietary antimicrobial agent, providing an even distribution of the active ingredient. The company’s says its manufacturing processes ensure that the antimicrobial agent is non-leaching and retains its efficacy through repeated launderings. Textiles made of PurThread fibers have been clinically-proven to continuously reduce the level of bioburden on soft surfaces. Soft and pliable, the company’s cutting-edge textiles are also available in the anti-odor sportswear brand PurThread Sport. Additionally, PurThread partners with leading consumer companies for end uses where its technology adds value, such as in military, industrial and home applications.